OMKAR PHARMACHEM LIMITED

WELCOME TO OMKAR PHARMACHEM LIMITED

Omkar Pharmachem Limited was established in year 1995.
The Company has been listed in BSE (Bombay Stock Exchange) and ASE (Ahmedabad Stock Exchange).

Profile Of Board Of Directors

1.	Mr. Parminder Sharma
	Mr. Parminder Sharma, aged 43 years is a qualified person having about 19 years of experience in corporate field. He is a director of the company since 14^th November, 2003.
2.	Anurag Sharma
	Mr. Anurag Sharma, aged 65 years is a Master in Commerce having about 26 years of experience in corporate field. He is a Managing Director of the company since 30^th August, 2001. He is a senior business executive having exposure in various areas of operations of company/ different business segments. He has expertise in successful implementation of many business ventures.
3.	Mamta Pachauri
	Ms. Mamta Pachauri, aged 39 years is 12^th pass. She is an independent woman director of the company since 31st March, 2015.
4.	Janak Raj Sharma
	Mr. Janak Raj Sharma aged 64 years is Graduate and has rich experience in the field of Corporate Management and Advisory. He is an independent Director of company. He is director of the company since 13^th February, 2016.
5.	Surender Singh Bindra
	Mr. Surender Singh Bindra, aged 67 years is a Director of the Company since 16th August, 1999. He has vacated his office w.e.f. 13^th February, 2016.

Investors

Ballot Forms
Postal Ballot Result
Scrutinizer Report
Notices
Corporate Policies
Important Dates
BSE Code - 532167, ASE Code- 42227
Commencement Certificate
Certificate of Incorporation
Quarterly compliance
- 30th Sept 2019
  - Corporate Governance Report
  - Share Holding Pattern
  - Unaudited Quarterly Result
  - Related Party Transaction
- 30th June 2019
  - Corprate Governance Report
  - Share Holding Pattern
  - Unaudited Quarterly Result
- 31st March 2019
  - Corprate Governance Report
  - Share Holding Pattern
  - Audited Quarterly Yearly Financial Result
  - Related Party Transaction
- 31st Dec 2018
  - Corprate Governance Report
  - Unaudited Quarterly Resultst
  - Share Holding Pattern
- 30th Sept 2018
  - Corprate Governance Report
  - Unaudited Quarterly Resultst
  - Share Holding Pattern
- 30th June 2018
  - Corprate Governance Report
  - Unaudited Quarterly Resultst
  - Share Holding Pattern
- 31st March 2018
  - Corporate Governance Report
  - Share Holding Pattern
  - Audited Quarterly Yearly Financial Result
- 31st Dec 2017
  - Corporate Governance Report
  - Unaudited Quarterly Result
  - Share Holding Pattern
- 30th Sep 2017
  - Corporate Governance Report
  - Unaudited Quarterly Result
  - Share Holding Pattern
- 30th June 2017
  - Corporate Governance Report
  - Unaudited Quarterly Result
  - Share Holding Pattern
- 31st March 2017
  - Audited Quarterly/Yearly Results
  - Corporate Governance Report
  - Share Holding Pattern
- 31st Dec 2016
  - Unaudited Quarterly Result
  - Corporate Governance Report
  - Share Holding Pattern
- 30th Sept 2016
  - Unaudited Quarterly Result
  - Corporate Governance Report
  - Share Holding Pattern
- 30th June 2016
  - Unaudited Quarterly Result
  - Corporate Governance Report
  - Share Holding Pattern
- 31st March 2016
  - Audited Quarterly Result
  - Corporate Governance Report
  - Share Holding Pattern
- 31st Dec 2015
  - Corporate Governance
  - Shareholding Pattern
- 30th Sep 2015
  - Unaudited Quarterly Result
  - Corporate GOVERNANCE
  - Shareholding Pattern
- 30th June 2015
  - Latest Un-Audited Quarterly Result
  - Corporate GOVERNANCE
  - Share holding Pattern
- 31st March 2015
  - Latest Un-Audited Quarterly Result
  - Corporate GOVERNANCE
  - Share holding Pattern
- 31st Dec 2014
  - Latest Un-Audited Quarterly Result
  - Corporate GOVERNANCE
  - Share holding Pattern
- 30th Sep 2014
  - Latest Un-Audited Quarterly Result
  - Corporate GOVERNANCE
  - Share holding Pattern
- 30th June 2014
  - Latest Un-Audited Quarterly Result
  - Corporate GOVERNANCE
  - Share holding Pattern
- 31st March 2014
  - Latest Un-Audited Quarterly Result
  - Corporate GOVERNANCE
  - Share holding Pattern
- 31st Dec 2013
  - Latest Un-Audited Quarterly Result
  - Corporate GOVERNANCE
  - Share holding Pattern
- 30th Sep 2013
  - Latest Un-Audited Quarterly Result
  - Corporate GOVERNANCE
  - Share holding Pattern
- 30th June 2013
  - Latest Un-Audited Quarterly Result
  - Corporate GOVERNANCE
  - Share holding Pattern
- 31st March 2013
  - Latest Un-Audited Quarterly Result
  - Corporate GOVERNANCE
  - Share holding Pattern
Policies
Investors Grievances
- Officers handling investors Grivances
Investor Correspondence
- Investor Correspondence

Annual Reports

Business

The main objects of the Company are related to pharmaceuticals and chemicals
Industry structure and development
- India's Pharmaceutical Industry: An overview -Size of India's pharmaceutical sales were an estimated $20 billion in2014 and the forecast indicates an average growth of 10.3 percent annually in 2014-18 (in nominal local-currency terms) to reach $33.8 billion. This growth will be driven by increasing personal incomes and the escalation of chronic diseases. India's pharmaceutical market is dominated by generic drugs, which account for around 75 percent of the market by volume. Supplied mainly by domestic companies, generics have helped to keep pharmaceutical prices low and the market is expected to continue expanding rapidly. Still, India's growing middle class is increasing demand for more advanced and costly medicines. Although domestic pharmaceutical companies were established primarily to supply the local market, they have taken advantage of their low labor and research costs to export generic drugs to developed countries, notably the U.S, its largest export market. India is also a major supplier to other emerging markets and has become the biggest supplier to UN health care programs. Domestic and international pharmaceutical companies operating in India face issues ranging from the new Drug Price Control Order (DPCO), which prescribes a ceiling on the prices of several essential medicines, to drug and clinical trial quality, patent issues, and the misclassification of medical devices.
Overall Review, Opportunities and challenges
- Since last many years the company has not done any manufacturing or other business activity. Due to current tough market situation, the company has decided not to proceed further for starting commercial activity and to wait till appropriate environment is established.

Composition of Various Committees

The composition of different committees of Board of Directors is as under:
- Audit Committee
  - Mamta Pachauri: Chairman; Parminder Sharma: Member; Janak Raj Sharma: Member w.e.f. 13.02.2016; S. S. Bindra: Member upto 13.02.2016
- Nomination & Remuneration Committees Composition
  - Mamta Pachauri: Chairman; Parminder Sharma: Member; Janak Raj Sharma: Member w.e.f. 13.02.2016; S. S. Bindra: Member upto 13.02.2016
- Stake holders Relationship Committees Composition
  - Parminder Sharma: Member; Janak Raj Sharma: Member w.e.f. 13.02.2016; Ms. Mamta Pachauri member w.e.f. 30.03.2019; S. S. Bindra: Member upto 13.02.2016
- CSR Committees composition
  - No such committee as the same is not applicable to the Company

KMP Compliance Officer and RTA

Key Managerial Personnel of the Company are as under:
- Anurag Sharma , Managing Director, DIN-02289261, Address: A-727 Sarita Vihar, New Delhi 110076
- Gaurav Kathuria, Chief Financial Officer Address:S-59,Gali No- 2, Block S, South Anarkalikrishna Nagar Delhi 110051
- Pankaj Singh, Company Secretary and Compliance Officer Address: A-136, Vivek Vihar, Phase-1, East Delhi, New Delhi-110095
Registrar & Share Transfer Agents:
- Alankit Assignments Limited 205-208, Anarkali Complex, Jhandewalan Extention, New Delhi – 110055

1.	Company’s Registered Office Address:
	501, Mahakant Building, Opposite V. S. Hospital,
	Ashram Road, Ellisbridge,
	Ahmedabad - 380006, GUJARAT
2.	Contact Person Name and Numbers:
	Company Secretary: Pankaj Mahadeo Singh +91-9899887583
3.	E-mail: investors.opl@gmail.com